Researchers review controversial effects of fecal microbiota transplantation (FMT) on immune checkpoint inhibitor therapy. While some studies show improved cancer outcomes, others reveal no benefit or adverse effects, highlighting the complex relationship between gut bacteria and cancer treatment success.

Researchers discovered immune checkpoint inhibitors (ICIs)—revolutionary cancer drugs—significantly increase the risk of cholestasis, a rare bile buildup that damages the liver. Younger patients (<65) and those receiving anti-PD-1 drugs face higher risk. Women develop symptoms earlier than men. Rigorous liver monitoring is urged.

This review systematically analyzes computational frameworks that integrate multi-omics data (genomics, transcriptomics, proteomics) to transform antagonistic drug interactions into synergistic combinations. By evaluating AI-driven models like AuDNNsynergy and DrugComboRanker, it demonstrates how these tools optimize cancer therapies, overcoming drug resistance and improving efficacy while reducing experimental screening burdens.

This review critically assesses the influence of intratumoral microbial metabolites on the tumor microenvironment (TME) and immunotherapy, which are comprehensively examined in regulating immune responses and tumor progression. Furthermore, we investigate the potential of these metabolites to augment the efficacy of cancer immunotherapies, with particular emphasis on immune checkpoint inhibitors.

A current study by the German Familial Colorectal Cancer Consortium is looking at the question of which people with Lynch syndrome are at an increased risk of developing a second colorectal cancer. Researchers from the University Hospital Bonn (UKB), the University of Bonn and the University of Leipzig have now published their findings in the journal "Clinical Gastroenterology and Hepatology".